The successful closing of the rights issue in early September and subsequently
the election of the new board of Directors in SoftOX Solutions AS on September
12th, formed a small, but important, formal step forward towards a new future
for the businesses within the SoftOx group.

The sole focus for SoftOx Solutions AS in the near term will be the funding and
advancement of phase II clinical trial for the company's project in
Ventilator-Associated Pneumonia, under the leadership of Professor Thomas
Bjarnsholt from Copenhagen University.

Efforts to spin off the skin & wound business, which was initiated by the
previous board, will be continued by the new board.

Once the formal restructuring of the group has been completed, Thomas Bjarnsholt
will step into the CEO role, and in the interim, the board has appointed CFO
Ingrid Juven to take the role of 'daglig leder' in charge of the daily
management of the Norwegian public entity.

For any questions please contact:  
Ingrid Juven, CFO of SoftOx Solutions AS  
Mail: ir@soft-ox.com  
Phone: Ingrid Juven: (+47) 918 76 165
 
About SoftOx Solutions AS:
SoftOx Solutions AS (SoftOx) is a Medtech, and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes the holding
company SoftOx Solutions AS, the Malmö subsidiary Water Innovation AB, and
subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is
developing a highly effective antimicrobial solution for biofilm, viral, and
antimicrobial-resistant infections. The patent-protected technology is based on
extensive research and development in partnership with leading Nordic research
institutes. 

For more information on SoftOx, visit www.soft-ox.com